Option chain shows key data for Surrozen's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Surrozen.

Surrozen (NASDAQ:SRZN) Stock, Option Chain

Surrozen

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).

May,30,,2024,,Brazil.,In,This,Photo,Illustration,,The,Worthington

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

FHTX

KSCP

PHIN

SRZN

This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Penny Stocks

Small Cap

Intraday Update

Movers

AEON

BIOR

BORR

CXAI

DOMA

DOYU

EIGR

GCTS

HGAS

HTCR

IMCC

INLX

IREN

IRON

MDIA

MESO

MMAT

NDRA

NVVE

ONDS

ORGS

OUST

PLSE

SBEV

SBFM

SGRP

SHCR

TCOM

TPET

VSTE

ZPTA

Shares of  Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expected fourth-quarter financial results.

Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

pharma lab worker ai

Biotech

Equities

Health Care

Financing

Offerings

General

Surrozen engages in a private placement, aiming to raise approximately $192.5 million in gross proceeds. Updates on SZN-043 Phase 1a trial reveal promising safety, tolerability, and effects on liver function.

Why Is Regenerative Medicine-Focused Surrozen Stock Trading Lower On Monday?

Surrozen Inc

Earnings

Press Releases

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Surrozen to Present at Upcoming Healthcare Investor Conferences

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

Legal

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Coherus Oncology

Climb Bio

Coya Therapeutics

Elutia

Entera Bio

ESSA Pharma

Forte Biosciences

HilleVax

Insight Molecular Diagnostics Inc. - Common Stock

Insight Molecular

Immunic

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

IO Biotech

Invivyd

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Macrogenics

OKYO Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

ProKidney Corp. - Class A Ordinary Shares

ProKidney

TScan Therapeutics

Tenaya Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

XBiotech

HC Wainwright & Co.

Guggenheim

B of A Securities

Comments

Surrozen

Surrozen (SRZN) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell